| Autor: |
Elghawy O; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Barsouk A; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Reed-Guy L; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Stalker M; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Sussman J; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Robinson K; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Kosteva J; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Singh A; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Cohen RB; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Langer C; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Ciunci C; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., D'Avella C; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Sun L; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Marmarelis ME; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Aggarwal C; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.. Electronic address: Charu.Aggarwal@pennmedicine.upenn.edu. |
| Abstrakt: |
Competing Interests: Disclosure LS reports consulting with Regeneron, MJH sciences, GenMab, Seagen, and Bayer; and institutional research funding from Blueprint Research, Seagen Research, Erasca, Abbvie, Immunocore and IO Biotech Research outside the submitted work. RC reports advisory roles in Ono pharmaceutical and Actuate Therapuetics and institutional funding from Innate Pharma, Xencor, AstraZeneca, F-star Biotechnology, Chugai Pharma and Catargia Ab. CL reports research funding (all institutional) from Merck, Trizell, Eli Lilly, Takeda, Astra Zeneca, Johnson and Johnson; consultative/advisory roles with Merck, BI, AZ, Genentech/Roche, Takeda, Amgen, Gilead, Regeneron, Novocure, Foundation Medicine, and Pfizer; prior medical writing support from Takeda, Merck and Novartis. MM reports researching funding from Eli Lilly (Inst), Trizell (Inst), AstraZeneca (Inst); consulting role with Astra Zeneca, Novocure, Boehringer Ingelheim; stock in Gilead Sciences, Portola Pharmaceuticals, Merck, Bluebird Bio, Johnson & Johnson, Pfizer; previous medical writing support from Novartis. CA reports a consulting or advisory role for Genentech, Lilly, Celgene, Merck Sharp & Dohme, AstraZeneca, Blueprint Genetics, Shionogi, Daiichi Sankyo/Astra Zeneca, Sanofi/ Regeneron, Eisai, BeiGene, Turning Point Therapeutics, Pfizer, Janssen, Boehringer Ingelheim and research funding to institution from Genentech/Roche, Incyte, Macrogenics, Merck Sharp & Dohme, and AstraZeneca. All other authors have no conflicts of interest to disclose |
Full Text from ScienceDirect